<DOC>
	<DOCNO>NCT00198068</DOCNO>
	<brief_summary>The PROMISSE Study observational study 700 pregnant patient , enrol nine major clinical center . The purpose study 1 ) determine whether certain protein ( call complement split product ) injure healthy organ use predict poor pregnancy outcome patient systemic lupus erythematosus ( SLE ) anti-phospholipid syndrome ( APS ) , and/or 2 ) determine whether elevated level circulate antiangiogenic factor predict pregnancy complication patient aPL antibody and/or SLE .</brief_summary>
	<brief_title>Predictors Pregnancy Outcome Systemic Lupus Erythematosus ( SLE ) Antiphospholipid Syndrome ( APS )</brief_title>
	<detailed_description>Thrombosis pregnancy loss common feature systemic lupus erythematosus ( SLE ) , particularly presence antiphospholipid ( aPL ) antibody . The vivo mechanism aPL antibody lead vascular event , specifically , recurrent fetal loss largely unknown . Studies mouse model antiphospholipid antibody syndrome ( APS ) indicate vivo complement activation necessary fetal loss cause aPL antibody . This study represent effort translate research observations potential role complement activation pathogenesis aPL antibody-mediated pregnancy loss clinically relevant human study . In addition , study human mice show 1 ) balance circulate angiogenic antiangiogenic factor predict preeclampsia fetal growth restriction healthy woman , 2 ) circulate antiangiogenic factor cause endothelial dysfunction abnormal placental development animal model , 3 ) complement activation lead elevate level circulate antiangiogenic factor complement inhibition prevents increase level antiangiogenic factor , placental dysfunction fetal growth restriction mouse model APS . This study permit test hypothesis , like healthy woman , balance circulate angiogenic antiangiogenic factor predict complication woman SLE APS translate finding animal model human . The PROMISSE Study prospective observational study follow 700 pregnant patient group analyzed accord presence absence aPL antibody preexist SLE . The patient follow regularly course pregnancy , collect medical obstetrical information well serial blood specimen complement cytokine assay . The data obtain analyze used identify mechanisms predictor poor fetal outcome . We expect insight provide study suggest mean prevent , arrest modify condition .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<mesh_term>Antibodies , Antiphospholipid</mesh_term>
	<criteria>Patient pregnant live intrauterine pregnancy , define positive test elevate βHCG , ≤ 12 week gestation ( subject without aPL antibody ) ≤18 week ( subject aPL antibody ) Patient age 1845 able give inform consent , age &lt; 18 year parental consent Hematocrit &gt; 26 % For APL positive : aCL : IgG &gt; = 40 GPL unit ; IgM &gt; = 40 MPL unit Positive LAC ( RVVT , Kaolin , dilute TTI PTT LA ) Antiβ2GPI : IgG &gt; = 40 GPL unit ; IgM &gt; = 40 MPL unit For control subject : At least one successful pregnancy No history fetal death ( death conceptus ≥ 10 week ' gestation ) No 1 miscarriage &lt; 10 week ' gestation No history positive aPL local lab positive aPL core lab screen Not currently smoker No medical problem require chronic treatment Diabetes mellitus ( Type I Type II ) antedate pregnancy Multiple fetal gestation Known suspected hereditary complement deficiency ( define CH50 = 0 )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pregnancy outcome</keyword>
	<keyword>Systemic lupus erythematosus</keyword>
	<keyword>Antiphospholipid syndrome</keyword>
</DOC>